Skip to main content

Published on 13 March 2025

Manufacture of cannabis products for pilot trials under Article 8a NarcA

The manufacture of products containing narcotics with an effective concentration of cannabinoids (‘cannabis products’) that is used in the pilot trials in accordance with Art. 8a of the Narcotics Act (NarcA), requires an exceptional licence from the FOPH.

To manufacture cannabis products used in the pilot trials under Art. 8a NarcA, an exceptional licence from the FOPH is required, in accordance with Art. 8 para. 5 NarcA.

The public or private organisations responsible for conducting a pilot trial designate their own manufacturer(s). Interested manufacturers should apply for an exceptional licence to manufacture cannabis products together with the responsible organisation that intends to conduct a pilot trial and plans to submit a corresponding application to the FOPH.

Further information

Further information

Federal Office of Public Health FOPH

Prevention of Non-Communicable Diseases Division
Schwarzenburgstrasse 157
Switzerland - 3003 Bern